ECM
CRL icon

EagleClaw Capital Management’s Charles River Laboratories CRL Stock Holding History

EagleClaw Capital Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-15,705
Closed -$3.24M – 140
2024
Q2 		$3.24M Sell
15,705
-100
-0.6% -$22.7K 0.58% 49
2024
Q1 		$4.28M Sell
15,805
-310
-2% -$74K 0.78% 44
2023
Q4 		$3.81M Sell
16,115
-4,670
-22% -$918K 0.79% 42
2023
Q3 		$4.07M Buy
20,785
+375
+2% +$77K 0.92% 38
2023
Q2 		$4.29M Buy
20,410
+1,925
+10% +$383K 0.99% 37
2023
Q1 		$3.73M Buy
18,485
+475
+3% +$108K 0.88% 41
2022
Q4 		$3.92M Sell
18,010
-6,210
-26% -$1.36M 0.95% 39
2022
Q3 		$4.77M Buy
24,220
+9,500
+65% +$2.05M 1.33% 25
2022
Q2 		$3.15M Buy
14,720
+590
+4% +$144K 0.85% 40
2022
Q1 		$4.01M Buy
14,130
+10,135
+254% +$3.13M 0.92% 35
2021
Q4 		$1.5M Buy
+3,995
New +$1.55M 0.33% 66

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

EagleClaw Capital Management's CRL Position: Q3 2024 in Review

EagleClaw Capital Management sold out of Charles River Laboratories (CRL) in Q3 2024, closing a stake of 15,705 shares — an estimated $3.24M sold.

EagleClaw Capital Management first reported a position in CRL in Q4 2021 and held it in 11 quarters. The position peaked at $4.77M in Q3 2022. 628 funds tracked by Wall St. Rank hold CRL as of Q3 2024.

  • EagleClaw Capital Management reported no remaining Charles River Laboratories position as of Q3 2024 after selling out during the quarter.
  • EagleClaw Capital Management sold 15,705 Charles River Laboratories shares in Q3 2024, an estimated $3.24M.
  • EagleClaw Capital Management first reported a position in Charles River Laboratories in Q4 2021 and held it in 11 quarters.
  • EagleClaw Capital Management's Charles River Laboratories position peaked at $4.77M in Q3 2022.
  • 628 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2024.

Based on EagleClaw Capital Management's 13F filing for Q3 2024, filed 8 Nov 2024.